A5027165632- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Long-Term Effects of COVID-19
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peripheral Neuropathies and Disorders
- Neurological Complications and Syndromes
- COVID-19 and Mental Health
- Circadian rhythm and melatonin
- Parkinson's Disease Mechanisms and Treatments
- Obstructive Sleep Apnea Research
- Sympathectomy and Hyperhidrosis Treatments
- Botulinum Toxin and Related Neurological Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myasthenia Gravis and Thymoma
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Cerebral Venous Sinus Thrombosis
- Neurosurgical Procedures and Complications
- Psychosomatic Disorders and Their Treatments
- Neurogenetic and Muscular Disorders Research
- Infectious Encephalopathies and Encephalitis
- Mitochondrial Function and Pathology
- Nicotinic Acetylcholine Receptors Study
- Laser Applications in Dentistry and Medicine
- Infection Control and Ventilation
- Intracerebral and Subarachnoid Hemorrhage Research
University of Messina
2007-2024
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2011-2023
European Society of Anaesthesiology
2006
To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic (CM: 15 days/month), multiple preventive treatment failures.This is a prospective, cohort, study at 28 headache centers on consecutive affected by HFEM CM failures who were prescribed subcutaneous (225 mg monthly/675 quarterly) for 24 weeks. Primary endpoint was change monthly days (MMDs) (MHDs) weeks 21-24 compared...
Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine < 2 medication clusters a randomized controlled trial (RCT). We aimed assess real-world evidence (RWE), long-term effectiveness, tolerability, safety of people high-frequency episodic (HFEM) or chronic (CM) > 3 failures various comorbidities. A 48-week, prospective, multicenter (n = 26), cohort study assessed fremanezumab's safety, tolerability consecutive adults HFEM CM...
The introduction of monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP), or its receptor (CGRPr), revolutionized migraine management due to their high efficacy and few side effects. Data suggest that CGRP may even be implicated in circadian rhythm, but studies about effect anti-CGRP treatments on sleep are still lacking. aim present study was assess erenumab (70 140 mg per month), a human mAb CGRPr, chronotype chronic migraineurs; secondly, we assessed...
The COVID-19 outbreak has had a dramatic impact on the healthcare system due to rapid, worldwide spread of virus, highlighting several considerations best management infected patients and also potential risks prognostic factors in with pre-existing chronic diseases exposed virus. Neurodegenerative disorders are known be chronic, disabling that imply higher vulnerability infections, for this reason, it been suggested SARS-CoV-2 infection may have worse course these patients. In present study,...
This is a clinical report of 63‐year‐old woman, with 3‐year history severe episodes hypnic headache responding to low‐doses topiramate (25 mg at bedtime). Topiramate has been used the dosage 100 mg/day for prevention in one recent case benefit. confirms efficacy even using low‐dose regimen therapy.
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)-a monoclonal antibody targeting calcitonin-gene-related peptide (anti-CGRP mAb)-in high-frequency episodic migraine (HFEM) or chronic (CM). The primary endpoint was change in monthly days (MMD) for HFEM headache (MHD) CM at weeks 9-12 compared to baseline. secondary endpoints included changes analgesic intake (MAI), Numerical Rating Scale...
Osteosclerotic myeloma is a rare plasma cell disorder often associated with polyneuropathy. We describe young patient progressive polyneuropathy vertebral bone marrow lesions and unusual meningeal infiltration at cauda level. The diagnosis of osteosclerotic was confirmed by biopsy findings including the chromosome 13q14 deletion in 37% cells. Leptomeningeal involvement demonstrated spine magnetic resonance imaging gadolinium administration fat-suppression technique.
Several studies highlighted the presence of anxiety, depression and anger in headache patients, however results are not always consistent. The aim this work was to explore link between different components anger, level depression, trait state diagnostic parameters such as frequency duration attacks.Eighty patients referred Headache center Messina University Hospital G. Martino, aged 16 70 years (M=40.60; DS=14.64) were evaluated with State-Trait Anger Expression Inventory (STAXI-2), Anxiety...
The physician and patient come into close contact during botulinum toxin treatments, increasing the chances of COVID-19 infection. Therefore, it is essential to use an effective injection method that can prevent infection with SARS-CoV-2 virus. In order minimize risk transmission treatment in era, Italian Botulinum Toxin Network study group Society Neurology has prepared a video best practice recommendations on how organize work clinic performing treatments.
Abstract Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥8 days/month) or chronic (CM: ≥15 days/month), multiple preventive treatment failures. Methods This is a prospective, cohort, study at 28 headache centers on consecutive affected by HFEM CM failures who were prescribed subcutaneous (225 mg monthly/675 quarterly) for ≥ 24 weeks. Primary endpoint was change monthly days...
Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome classified as trigeminal autonomic cephalalgia. It characterized by repeated attacks of severe, strictly unilateral and short-lasting pain occurring with cranial features. The absolute response to indomethacin represents the diagnostic key. Unfortunately, often, treatment may cause adverse events, mostly gastrointestinal. We report case 53-year-old male affected CPH responding indomethacin, which had be withdrawn because...
Objective: To describe an atypical immunoreactivity against Purkinje cells and glia of rat cerebellum in a case transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP). Background: TTR‐FAP is autosomal dominant disease, usually presenting as progressive sensory or sensorimotor with autonomic disturbances. Case report: A 68‐year‐old man complained two‐year history severe orthostatic hypotension, diarrhea polyneuropathy. The neurological examination showed distal weakness at the four...